Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01855945 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
A Phase 1 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 1
- Development phase
- 627
- Enrollment target
NCT01855945 is a Phase 1 study that has completed, run by Novartis Vaccines. The registered enrollment target is 627 participants.
The verdict
NCT01855945, a Phase 1 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 627 participants
- Enrollment target
Study Summary
Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in children ages 3 to \<9 years, adolescents 9 to \<18 years, adults 18 to \<65 years and elderly 65 years and older.
Interventions
- BIOLOGICAL Swine Influenza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01855945
The ClinicalTrials.gov registry entry for NCT01855945 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 627 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Swine Influenza is the first listed.
NCT01855945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01855945 about?
NCT01855945 is a clinical study titled "Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.". Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in children ages 3 to \<9 years, adolescents 9 to \<18 years, adults 18 to \<65 years and elderly 65 years and older.
What is the current status of trial NCT01855945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 627 participants. The study started on 2013-05. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01855945?
The interventions under investigation include: Swine Influenza (BIOLOGICAL).
Who is sponsoring clinical trial NCT01855945?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.